Evoke Pharma, Inc. (EVOK) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -521.96K | -565.02K | -997.51K | -1.24M | -818.7K | -820.62K | -2.58M | -1.11M | -1.04M | -1.21M | -1.63M | -2.51M |
| Operating CF Margin % | -12.18% | -15.06% | -32.39% | -37.48% | -30.85% | -32.16% | -148.63% | -66% | -66.65% | -106.63% | -201.24% | -314.72% |
| Operating CF Growth % | 36.25% | 31.15% | 61.33% | -12.11% | 21.4% | 31.98% | -58.16% | 55.87% | 5.39% | 12.18% | -0.98% | -25.49% |
| Net Income | -1.16M | -1.57M | -1.31M | -1.19M | -1.31M | -1.27M | -1.58M | -1.99M | -1.69M | -1.87M | -2.24M | -1.8M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 104.25K | 84.38K | 0 | 0 | 0 | 254.03K | 0 | 281.76K | 280.14K | 284.57K | 354.97K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 250.23K | 143.8K | 142.44K | 403.64K | 257.61K | 251.24K | 124.66K | 295.01K | 165.5K | 163.21K | 160.96K | 24.6K |
| Working Capital Changes | 384.02K | 757.9K | 81.85K | -450.92K | 236.08K | 195.37K | -1.38M | 586.29K | 205.04K | 218.19K | 166.64K | -1.08M |
| Change in Receivables | -285.04K | -393.95K | -91.12K | -397.86K | -19.52K | -551.1K | -778.83K | 560.83K | -210.09K | -336.51K | -62.47K | 50.14K |
| Change in Inventory | 41.96K | -109.73K | -87.06K | 44.41K | 51.36K | 44.01K | -106.94K | 0 | 8.79K | -148.84K | -75.49K | 0 |
| Change in Payables | 328K | 807.09K | 440.01K | 353.62K | -188.08K | 242.62K | 343.6K | 192K | -17.87K | 229.38K | 251.61K | -86.38K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 0% | - | - | 0% | 0% | 0% | - | 0% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 38.9K | 0 | 25K | 3.5M | 2.98M | 295.7K | 7.54M | -119.3K | 0 | 0 | 0 | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 38.9K | 0 | 25K | 1000K | 1000K | 295.7K | 1000K | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | -191 | 0 | 824.51K | -119.3K | 0 | 0 | 0 | 0 |
| Net Change in Cash | -483.06K | -565.02K | -972.51K | 2.26M | 2.16M | -524.92K | 4.96M | -1.23M | -1.04M | -1.21M | -1.63M | -2.51M |
| Free Cash Flow | -521.96K | -565.02K | -997.51K | -1.24M | -818.7K | -820.62K | -2.58M | -1.11M | -1.04M | -1.21M | -1.63M | -2.51M |
| FCF Margin % | -12.18% | -15.06% | -32.39% | -37.48% | -30.85% | -32.16% | -148.63% | -66% | -66.65% | -106.63% | -201.24% | -314.72% |
| FCF Growth % | 36.25% | 31.15% | 61.33% | -12.11% | 21.4% | 31.98% | -58.16% | 55.87% | 5.39% | 12.18% | -0.98% | -25.49% |
| FCF per Share | -0.20 | -0.22 | -0.39 | -0.83 | -0.58 | -0.60 | -3.41 | -3.97 | -3.74 | -4.33 | -5.85 | -9.00 |
| FCF Conversion (FCF/Net Income) | 0.45x | 0.36x | 0.76x | 1.04x | 0.62x | 0.65x | 1.63x | 0.56x | 0.61x | 0.65x | 0.73x | 1.39x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |